AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
0.219
+0.006 (2.57%)
At close: Jan 21, 2025, 4:00 PM
0.233
+0.014 (6.43%)
After-hours: Jan 21, 2025, 7:57 PM EST
AIM ImmunoTech Revenue
AIM ImmunoTech had revenue of $35.00K in the quarter ending September 30, 2024, a decrease of -23.91%. This brings the company's revenue in the last twelve months to $190.00K, down -1.55% year-over-year. In the year 2023, AIM ImmunoTech had annual revenue of $202.00K with 43.26% growth.
Revenue (ttm)
$190.00K
Revenue Growth
-1.55%
P/S Ratio
60.30
Revenue / Employee
$6,786
Employees
28
Market Cap
13.99M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 202.00K | 61.00K | 43.26% |
Dec 31, 2022 | 141.00K | 6.00K | 4.44% |
Dec 31, 2021 | 135.00K | -28.00K | -17.18% |
Dec 31, 2020 | 163.00K | 23.00K | 16.43% |
Dec 31, 2019 | 140.00K | -227.00K | -61.85% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
AIM News
- 6 days ago - AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones - GlobeNewsWire
- 5 weeks ago - AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards - GlobeNewsWire
- 5 weeks ago - AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting - Business Wire
- 5 weeks ago - AIM ImmunoTech Reminds Shareholders to Vote “FOR” All Four Incumbent Board Members on the WHITE Universal Proxy Card - Business Wire
- 5 weeks ago - Kellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent Board - GlobeNewsWire
- 5 weeks ago - AIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board Members - Business Wire
- 5 weeks ago - AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue - GlobeNewsWire
- 5 weeks ago - Kellner Group Announces Support from Another Former AIM Senior Executive - GlobeNewsWire